Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. is a U.S.-based biomedical innovation company focused on developing therapeutic medical device technologies through partnerships with larger medical device companies. Its portfolio includes late-stage product candidates and strategic holdings centered on cardiovascular and surgical applications, with commercialization intended to be advanced through collaborators rather than a fully standalone sales model.

−153,8 %

99,4 %

−157,4 %

+1 169,2 %

6.45

6.43

— Orchestra BioMed Holdings, Inc.
%
AVIM Therapy0% Cardiovascular therapy platform developed for pacemaker-indicated hypertension patients.
Virtue SAB0% Sirolimus-based balloon therapy product candidate for vascular intervention.
FreeHold Surgical Products100% Intracorporeal organ retractors used in surgical procedures and sold in the U.S.
Partnership Revenue0% Collaborative development and commercialization arrangements with strategic partners.
Strategic Holdings0% Minority equity, royalty-stream and convertible interests in related device assets.

The company sells primarily to healthcare providers and medical device partners rather than to consumers...

  • Surgical hospitals and operating roomsprimary

    Buy FreeHold intracorporeal organ retractors for use in surgical procedures.

  • Medical device partnersprimary

    Collaborate on development, regulatory work and commercialization of AVIM Therapy and related assets.

  • Cardiology and electrophysiology care settingssecondary

    Potential end users for AVIM Therapy in pacemaker-indicated hypertension patients.

  • Vascular intervention providerssecondary

    Potential users of Virtue SAB in interventional cardiovascular procedures.

Orchestra BioMed is headquartered in the United States and its commercial product sales are currently limited to the U...

  • •Headquartered in the United States
  • •FreeHold product sales are currently only in the United States
  • •AVIM Therapy and Virtue SAB are built for broader global commercialization
  • •Partner networks may extend reach beyond the U.S. after approval
  • •Current revenue exposure is concentrated in U.S. healthcare markets

The company’s strategy is to advance late-stage therapeutic device candidates through pivotal clinical development...

01
Progress partnered cardiovascular programsmedium-term

Partnered development can accelerate regulatory and commercial pathways while limiting standalone build-out needs.

02
Expand value from late-stage device pipelinemedium-term

Late-stage assets can create value inflection points if clinical and regulatory milestones are achieved.

03
Support commercial FreeHold salesshort-term

The existing product line provides direct product revenue and operating experience.

The business depends on successful clinical development, regulatory approvals and partner execution, so setbacks in any...

high

Clinical and regulatory failure

AVIM Therapy and Virtue SAB require successful trials and approvals before broad commercialization.

Scope
Pipeline products
Materiality
high
high

Partner dependence

The business model relies on established device companies for development and commercialization support.

Scope
Medtronic, Terumo and other collaborators
Materiality
high
high

Supply-chain concentration

Key components for Virtue SAB are sourced from single manufacturers in China and Singapore.

Scope
Sirolimus and angioplasty balloons
Materiality
high
medium

Product liability and safety risk

Adverse events or labeling changes can reduce market acceptance and trigger legal or regulatory actions.

Scope
Approved or future therapeutic devices
Materiality
high
medium

Competitive pressure

Larger device companies may have broader product lines, stronger distribution and more resources.

Scope
Cardiovascular and surgical device markets
Materiality
medium
Collaboration revenue recognition
Can shift revenue between periods and affect comparability
Point-in-time product revenue
Quarterly revenue can be affected by shipment timing
R&D accrual estimates
Can materially affect operating expenses and liabilities
Fair value and impairment of strategic holdings
Can create non-cash gains, losses or impairment charges

ORAMED PHARMACEUTICALS INC.

ORMP · Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

FAMILY OFFICE OF AMERICA, INC.

FOFA · Surgical & Medical Instruments & Apparatus

Odyssey Health, Inc.

ODYY · Surgical & Medical Instruments & Apparatus

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

: 29/04/2026